American Medical AssociationIntervention Reduces “Death Rattle” in End-of-Life Care

Publication: JAMADesign: Multicenter, randomized, double-blind, placebo-controlled trial performed in six hospices in the Netherlands of 162 patients with a life expectancy of three or more days. Administration of subcutaneous scopolamine butylbromide, 20 mg four times a day (n = 79) or placebo (n=78) in the 157 patients included in the primary analysis.Results: A death rattle occurred in […]

Wyanoke GroupConflicting Guidelines Highlight Controversies in Osteoporosis Management

When preparing to treat a patient for osteoporosis, it might be wise to compare leading guidelines because guidelines from two key organizations often don’t agree. The ACP and the National Osteoporosis Foundation (NOF) have come up with guidelines that differ in terms of what therapies, how long to treat, how long between scans, and more. […]

American Society of HematologyCognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma

Publication: ASH Clinical NewsOriginal Source: Journal of the National Care InstituteDesign: Assessment of longitudinal changes in memory, attention, and executive function in men and women with lymphoma (n=248; 62.5% male) prior to and six months after initiation of chemotherapy. A group of age- and sex-matched people without cancer was used as a control arm (n=212; […]

American Society of Clinical OncologyOn the Absence of Sound

How could complete silence possibly be considered music (John Cage’s 4’33”), or a blank canvas a masterpiece of art (Robert Rauschenberg’s White Painting)? This oncology medical student explains how after truly listening to a dying patient’s wishes, the student’s silence provided the canvas for the patient’s thoughts, becoming an advocate for his needs: “Silence is […]

Haymarket MediaTreatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma

Reference Source: JAMA Network OpenDesign: Retrospective study of 8,953 patients from the National Cancer Database; compared the use of definitive treatment between 2004 and 2014 of 1,280 young adults (YAs, aged 18-39 years); 3,937 patients aged 40-64 years; and 3,756 patients age 65+.Results: Amputation – 8.1% (YAs), 5.5% (40-64), 5.3% (65+). Chemotherapy – 39.4% (YAs), […]

American Society of HematologyActivity of mRNA COVID-19 Vaccines in Patients with Lymphoid Malignancies

Publication: Blood AdvancesStudy Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls. Related Article: Efficacy […]

Everyday HealthBiden Announces New Actions to Fight COVID

The recent Delta variant explosion prompted President Biden to direct the Secretary of Education to do whatever it takes against governors who are trying to block and intimidate local school officials and educators from instituting mask mandates for children. Also, he instituted mandatory vaccines for nursing home workers and announced booster shots will be available […]

Haymarket MediaSwitching Antifibrotic Agents in Idiopathic Pulmonary Fibrosis (IPF)

Source: BMC Pulmonary MedicineFindings:  IPF patients who switched from one antifibrotic therapy to the alternative — whether from pirfenidone (Esbriet) to nintedanib (Ofev, Vargatef) or the other way around – had improved survival. This observation held true whether the reason for switch was disease progress or tolerance issues.Design: Multi-center retrospective cohort study; 262 patients